Opaleye Management Inc. - 10 Nov 2023 Form 4 Insider Report for Tracon Pharmaceuticals, Inc.

Role
10%+ Owner
Signature
Opaleye Management Inc., By: /s/ James Silverman, President
Issuer symbol
N/A
Transactions as of
10 Nov 2023
Net transactions value
-$1,401,571
Form type
4
Filing time
14 Nov 2023, 16:05:15 UTC
Previous filing
20 Sep 2023
Next filing
22 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TCON Common Stock, par value $0.001 per share Sale $1,272,123 -4,324,008 -100% $0.2942 0 10 Nov 2023 By Opaleye, L.P. F1, F3
transaction TCON Common Stock, par value $0.001 per share Sale $129,448 -440,000 -100% $0.2942 0 10 Nov 2023 By Managed account F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding TCON Prefunded Warrants 1,667,974 10 Nov 2023 Common Stock 1,667,974 $0.0100 By Opaleye,L.P. F1, F4
holding TCON Prefunded Warrants 1,358,993 10 Nov 2023 Common Stock 1,358,993 $0.0100 By Opaleye,L.P. F1, F4
holding TCON Prefunded Warrants 2,205,018 10 Nov 2023 Common Stock 2,205,018 $0.0100 By Opaleye, L.P. F1, F4
holding TCON Prefunded Warrants 2,013,999 10 Nov 2023 Common Stock 2,013,999 $0.0100 By Opaleye, L.P. F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Opaleye Management Inc. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Represents securities owned directly by Opaleye, L.P. (The "Fund"). As the investment manager of the Fund.
F2 Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to own the securities owned directly by the Managed Account beneficially.
F3 This transaction was executed in multiple trades at prices ranging from $0.21 to $0.375; the price reported above reflects the weighted average purchase price. The reporting person undertakes to provide upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased.
F4 The warrants may not be exercised to the extent that such exercise would cause the reporting person and its affiliates to beneficially own more than 19.99% of the Issuer's then outstanding common stock.